Sanofi (NASDAQ:SNY) Receives $61.50 Average PT from Analysts

Shares of Sanofi (NASDAQ:SNY - Get Free Report) have been assigned a consensus rating of "Buy" from the nine analysts that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $61.50.

SNY has been the topic of several analyst reports. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research note on Monday, June 2nd. BNP Paribas initiated coverage on shares of Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target on the stock. Barclays reissued an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Finally, Guggenheim reissued a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd.

Hedge Funds Weigh In On Sanofi

A number of hedge funds have recently added to or reduced their stakes in the company. Ameritas Advisory Services LLC acquired a new position in Sanofi during the second quarter valued at approximately $28,000. Accent Capital Management LLC bought a new stake in shares of Sanofi in the first quarter valued at approximately $29,000. Eastern Bank boosted its position in shares of Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after acquiring an additional 300 shares during the period. Bessemer Group Inc. boosted its position in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after acquiring an additional 242 shares during the period. Finally, Banque Transatlantique SA bought a new stake in shares of Sanofi in the first quarter valued at approximately $33,000. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Stock Up 0.5%

Shares of NASDAQ:SNY traded up $0.24 during trading hours on Thursday, reaching $50.37. The stock had a trading volume of 1,468,581 shares, compared to its average volume of 2,528,303. The firm's 50 day moving average is $49.57 and its 200-day moving average is $52.10. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. The stock has a market capitalization of $123.53 billion, a price-to-earnings ratio of 17.99, a P/E/G ratio of 1.14 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The firm had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. Sanofi's quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.78 EPS. Research analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.